SK Bioscience Kim Hoon CTO Promoted to Global R&BD Head

Kim Hoon, Global R&BD Head at SK Bioscience.

[Asia Economy Reporter Lee Gwanju] SK Bioscience announced on the 1st that Kim Hoon, CTO (Chief Technology Officer) and head of the U.S. branch, has been promoted and appointed as the global R&BD (Research & Business Development) representative effective from the 7th of this month.

Under the leadership of President Ahn Jae-yong, SK Bioscience plans to continue its growth advancement and take the lead in protecting public health through a specialized management structure where the new representative Kim Hoon will be fully responsible for global business, research and development, and production.

New representative Kim joined SK Chemicals in 2008, served as head of the Bio Division in 2014, and as head of the VAX Development Headquarters in 2016. He was appointed as the inaugural CTO when SK Bioscience was launched in 2018.

Since then, he has led global collaborations with international organizations such as the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI), as well as the development, production, and contract development and manufacturing organization (CDMO) of various vaccines including Korea’s first domestic COVID-19 vaccine, Skycovione.

Earlier in October, Kim was concurrently appointed as the head of the U.S. branch, 'SK bioscience USA.' He plans to open an office in Boston, U.S., early next year and establish and implement global strategies for vaccine and bio businesses while traveling between Korea and the U.S.

SK Bioscience intends to fully activate its growth strategy based on a specialized management system. Utilizing the know-how and capital accumulated during the COVID-19 pandemic, the company plans to strategically implement ▲ follow-up responses to the COVID endemic ▲ strengthening vaccine business and expanding global markets ▲ securing cell and gene therapy (CGT) and next-generation platform technologies ▲ enhancing global partnerships to prepare for the next pandemic ▲ qualitative and quantitative expansion of R&D and production infrastructure ▲ continuous strengthening of management infrastructure.

Additionally, to expand its business beyond vaccines into the bio sector, SK Bioscience aims to solidify its position as an innovative global partner in the vaccine and bio fields by promoting CDMO, mergers and acquisitions (M&A), and joint ventures (JV) with global companies and expanding its global network.

This content was produced with the assistance of AI translation services.